Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study
PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.
254 Results
PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.
Results from an exploratory analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)
Biodesix recently added Biognosys' Proteomics to their capabiltites.
Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.
Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.
In addition to the $15 million of series shares in 2013 and 2014, Biodesix brought in another $12 million, for total proceeds of $27 million from the sale.
VeriStrat blood-based prognostic and predictive proteomics test has been approved for in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).
Biodesix has closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides Biodesix®with up to $20 million of capital.
Biodesix increases the size of its recent offering of series E preferred shares in a follow-on sale; Total series E preferred shares of $14.4 million.